References
- American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033-46
- Cavender MA, Steg G, Smith SC, et al. Impact of diabetes on hospitalization for heart failure, cardiovascular events, and death: Outcomes at 4 years from the REACH registry. Circulation 2015;132:923-31
- Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. (CS217080A.) Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2011. Available at: https://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf [Last accessed July 30, 2017]
- Zhuo X, Zhang P, Hoerger T. Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. Am J Prev Med 2013;45:253-61
- Fraze T, Jiang HJ, Burgess J. Hospital stays for patients with diabetes, 2008. (Statistical brief #93.) Rockville (MD): Healthcare Cost and Utilization Project, August 2010. Available at: www.hcup-us.ahrq.gov/reports/statbriefs/sb93.jsp [Last accessed July 30, 2017]
- Dunlay SM, Redfield MM, Jiang R, et al. Care in the last year of life for community patients with heart failure. Circ Heart Fail 2015;8:489-96
- Unroe KT, Greiner MA, Hernandez AF, et al. Resource use in the last 6 months of life among Medicare beneficiaries with heart failure, 2000–2007. Arch Int Med 2011;171:196-203
- Obi EN, Swindle JP, Turner ST, et al. Health care costs for patients with heart failure escalate nearly 3-fold in final months of life. J Manag Care Spec Pharm 2016;22:1446-56
- Solberg LI, Engebretson KI, Sperl-Hillen JM, et al. Are claims data accurate enough to identify patients with performance measures or quality improvement? The case of diabetes, heart disease, and depression. Am J Med Qual 2006;21:238-45
- Joyce AT, Iacoviello JM, Nag S, et al. End-stage renal disease-associated managed care costs among patients with and without diabetes. Diabetes Care 2004;27:2829-35
- Stuart EA. Matching methods for causal inference: a review and a look forward. Stat Sci 2010;25:1-21
- Lumley T, Diehr P, Emerson S, Chen L. The importance of the normality assumption in large public health data sets. Annu Rev Public Health 2002;23:151-69
- Guidance for Industry: Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. Silver Spring, MD: Center for Drug Evaluation and Research (CDER), December 2008. Available at: http://www.fda.Gov/Downloads/Drugs/Guidancecompli-anceregulatoryinformation/Guidances/Ucm071627.pdf [Last accessed 11 October 2017]
- Pfeffer MA, Claggett B, Diaz R, et al.; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247-57
- Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26
- White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35
- Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-22
- Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-44
- Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-57
- Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28
- American Diabetes Association. Summary of revisions: standards of medical care – 2018. Diabetes Care 2018;41(Suppl 1):S4-S6
- Wacholder S, Silverman DT, McLaughlin JK, Mandel JS. Selection of controls in case–control studies. Am J Epidemiol 1992;135:1019-28